Key Statistics
Client
Sanofi US
Year
2019
PM Group Office
Boston
Cost
Confidential
Size
6,000 sq ft

At its Framingham MA site, Sanofi US recently developed an MSAT (Manufacturing Sciences and Technology) pilot plant to produce next-generation products in a 500L single use bioreactor process. The pilot plant was designed to integrate into the existing operating GMP facility with minimal operational impact. 

Do you have a pharmaceutical project? Talk to one of our experts.

Andy Rayner
Andy Rayner

Pharmaceutical Sector Director

The project

PM Group was responsible for developing this project from concept through to issue of construction documents.  Drawing on previous project experiences, our multi-discipline A&E team executed the project in close collaboration with Sanofi end users, Sanofi engineering teams and the construction team.  Our services included concept design, BoD, field verification, detailed design and construction administration. We supported on the project through to construction and commissioning.

Minimising impact on operations

As a schedule driven project, solutions were implemented to meet the individual GMP requirements of the pilot plant without impacting the existing operating facility. For example design of a point-of-use cooler was implemented to achieve the required ambient WFI dispensing with minimal impact on existing systems. Similarly, the bulk gas storage tanks were designed and operational prior to shutdown. This facilitated early process and equipment test runs.

More about Sanofi

Sanofi US focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat.  Sanofi currently provides more than 25 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.

Andy Rayner

Pharmaceutical Sector Director